ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Spironolactone Prevents Calcineurin Inhibitors Toxicity in Renal Allografts. Preliminary Report

J. Martinez, I. Vargas, B. Chagolla, A. Ramirez, J. Bermudez.

Nephrology, Hospital General "Dr Miguel Silva", Morelia, Michoacan, Mexico.

Meeting: 2015 American Transplant Congress

Abstract number: B123

Keywords: Calcineurin, Nephrotoxicity

Session Information

Session Name: Poster Session B: Kidney Complications: Late Graft Failure

Session Type: Poster Session

Date: Sunday, May 3, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Introduction: Calcineurin inhibitors (CI) introduction was a transcendental event in the transplant medicine history. Actually, CI are considered the cornerstone in the immunosuppression treatment because they have a better short term renal transplant outcomes. However, long term allograft survival can be decreased related to their potential nephrotoxicity. The aim of the present study was to evaluate allograft CI nephrotoxicity prevention with the use of spironolactone.

Methods: A prospective randomized open label controlled trial was conducted in renal transplant patients with immunosuppression based on CI from Nov-2012 to Oct-2015. Patients were randomly allocated to 50mg spironolactone daily from the 8th post-transplant day through follow-up (Treatment group) or not spironolactone (ctrl group). Renal function and histological abnormalities on renal allograft biopsy were evaluated during follow-up.

Results: In this preliminary report 28 patients were analyzed. Ten (35%) and 18 (65%) patients were included on treatment and control group, respectively. No basal differences in demographics, immunological risk, donor type, and CI inhibitor used were found between groups. CI T-12 serum levels through the follow-up were similar in both groups. Basal serum creatinine (SCr) was 1.2[1.0-1.4] mg/dL and 1.1[0.9-1.4] mg/dL (p=NS), and at the end of follow up 1.2[1.0-1.5] mg/dL and 1.2[1-1.6] mg/dL (p=NS) in treatment and control group, respectively. SCr delta change from basal to de end of follow was 0.03[-0.03 a 0.09] mg/dL in treatment group and 0.2[0.08 a 0.36] mg/dL in control group (p=0.04). Acute CI toxicity was present in 9 (90%) patients at 116±63 post-transplant days in the treatment group and 12(67%) patients at 120±88 post-transplant days in the control group (p=NS). Chronic CI toxicity was found in 1 (10%) patient at 287±63 post-transplant days in the treatment group and 8 (44%) patients at 264±137 post-transplant days in the control group (p=0.06). Inflammatory infiltrate percentage was lower for treatment group (2±5% vs 10±15%, p=0.04. Free chronic CI toxicity survive was better in treatment group compared with control group (long Rank 0.04). No adverse events were seen with spironolactone use.

Conclusions: Spironolactone could reduce renal allograft dysfunction and prevents chronic IC toxicity. This results should be confirmed in a study with a bigger sample and longer follow up.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Martinez J, Vargas I, Chagolla B, Ramirez A, Bermudez J. Spironolactone Prevents Calcineurin Inhibitors Toxicity in Renal Allografts. Preliminary Report [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/spironolactone-prevents-calcineurin-inhibitors-toxicity-in-renal-allografts-preliminary-report/. Accessed May 9, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences